{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,25]],"date-time":"2026-02-25T11:34:13Z","timestamp":1772019253491,"version":"3.50.1"},"reference-count":11,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2020,12,14]],"date-time":"2020-12-14T00:00:00Z","timestamp":1607904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,12,14]],"date-time":"2020-12-14T00:00:00Z","timestamp":1607904000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Br J Cancer"],"published-print":{"date-parts":[[2021,3,16]]},"DOI":"10.1038\/s41416-020-01215-7","type":"journal-article","created":{"date-parts":[[2020,12,14]],"date-time":"2020-12-14T11:13:36Z","timestamp":1607944416000},"page":"1179-1180","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Response to Comment on \u201cHeterogeneity in PD-L1 expression in malignant peritoneal mesothelioma with systemic or intraperitoneal chemotherapy\u201d"],"prefix":"10.1038","volume":"124","author":[{"given":"Michael G.","family":"White","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0226-5005","authenticated-orcid":false,"given":"Oliver S.","family":"Eng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,12,14]]},"reference":[{"key":"1215_CR1","doi-asserted-by":"publisher","unstructured":"White, M. G., Schulte, J. J., Xue, L., Berger, Y., Schuitevoerder, D., Vining, C. C. et al. Heterogeneity in PD-L1 expression in malignant peritoneal mesothelioma with systemic or intraperitoneal chemotherapy. Br. J. Cancer https:\/\/doi.org\/10.1038\/s41416-020-01130-x (2020).","DOI":"10.1038\/s41416-020-01130-x"},{"key":"1215_CR2","doi-asserted-by":"publisher","first-page":"2018","DOI":"10.1245\/s10434-018-6499-1","volume":"25","author":"V Verma","year":"2018","unstructured":"Verma, V., Sleightholm, R. L., Rusthoven, C. G., Koshy, M., Sher, D. J., Grover, S. et al. Malignant peritoneal mesothelioma: national practice patterns, outcomes, and predictors of survival. Ann. Surg. Oncol. 25, 2018\u20132026 (2018).","journal-title":"Ann. Surg. Oncol."},{"key":"1215_CR3","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1038\/s41586-019-1914-8","volume":"577","author":"R Cabrita","year":"2020","unstructured":"Cabrita, R., Lauss, M., Sanna, A., Donia, M., Skaarup Larsen, M., Mitra, S. et al. Tertiary lymphoid structures improve immunotherapy and survival in melanoma. Nature 577, 561\u2013565 (2020).","journal-title":"Nature"},{"key":"1215_CR4","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1038\/s41586-019-1922-8","volume":"577","author":"BA Helmink","year":"2020","unstructured":"Helmink, B. A., Reddy, S. M., Gao, J., Zhang, S., Basar, R., Thakur, R. et al. B cells and tertiary lymphoid structures promote immunotherapy response. Nature 577, 549\u2013555 (2020).","journal-title":"Nature"},{"key":"1215_CR5","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1038\/s41586-019-1906-8","volume":"577","author":"F Petitprez","year":"2020","unstructured":"Petitprez, F., deReynies, A., Keung, E. Z., Chen, T. W., Sun, C. M., Calderarao, J. et al. B cells are associated with survival and immunotherapy response in sarcoma. Nature 577, 556\u2013560 (2020).","journal-title":"Nature"},{"key":"1215_CR6","doi-asserted-by":"publisher","first-page":"4363","DOI":"10.1158\/1078-0432.CCR-18-0468","volume":"25","author":"AA Kraya","year":"2019","unstructured":"Kraya, A. A., Maxwell, K. N., Wubbenhorst, B., Wenz, B. M., Pluta, J., Rech, A. J. et al. Genomic Signatures Predict the Immunogenicity of BRCA-Deficient Breast Cancer. Clin. Cancer Res. 25, 4363\u20134374 (2019).","journal-title":"Clin. Cancer Res"},{"key":"1215_CR7","doi-asserted-by":"publisher","first-page":"942","DOI":"10.1158\/2326-6066.CIR-17-0375","volume":"5","author":"DT Le","year":"2017","unstructured":"Le, D. T., Hubbard-Lucey, V. M., Morse, M. A., Heery, C. R., Dwyer, A., Marsilje, T. H. et al. A blueprint to advance colorectal cancer immunotherapies. Cancer Immunol. Res. 5, 942\u2013949 (2017).","journal-title":"Cancer Immunol. Res."},{"key":"1215_CR8","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1158\/2159-8290.CD-15-1545","volume":"6","author":"PL Chen","year":"2016","unstructured":"Chen, P. L., Roh, W., Reuben, A., Cooper, Z. A., Spencer, C. N., Prieto, P. A. et al. Analysis of immune signatures in longitudinal tumor samples yields insight into biomarkers of response and mechanisms of resistance to immune checkpoint blockade. Cancer Discov. 6, 827\u2013837 (2016).","journal-title":"Cancer Discov."},{"key":"1215_CR9","doi-asserted-by":"publisher","first-page":"S339","DOI":"10.1016\/j.jtho.2018.08.277","volume":"13","author":"A Desai","year":"2018","unstructured":"Desai, A., Karrison, T., Rose, B., Tan, Y., Hill, B., Pemberton, E. et al. OA08.03 phase II trial of pembrolizumab (NCT02399371) in previously-treated malignant mesothelioma (MM): final analysis. J. Thorac. Oncol. 13, S339 (2018).","journal-title":"J. Thorac. Oncol."},{"key":"1215_CR10","doi-asserted-by":"publisher","unstructured":"Franko, J., Brahmbhatt, R., Tee, M., Raman, S., Ferrel, B., Gorvet, M. et al. Cellular immunoprofile of peritoneal environment during a HIPEC procedure. Ann. Surg. Oncol. https:\/\/doi.org\/10.1245\/s10434-020-08870-3 (2020).","DOI":"10.1245\/s10434-020-08870-3"},{"key":"1215_CR11","doi-asserted-by":"publisher","unstructured":"Miller, A. M., Lemki-Miltner, C. D., Blackwell, S., Tomanek-Chalkley, A., Gibson-Corely, K. N., Coleman, K. L. et al. Intraperitoneal CMP-001: a novel immunotherapy for treating peritoneal carcinomatosis of gastrointestinal and pancreaticobiliary cancer. Ann. Surg. Oncol. https:\/\/doi.org\/10.1245\/s10434-020-08591-7 (2020).","DOI":"10.1245\/s10434-020-08591-7"}],"container-title":["British Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41416-020-01215-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41416-020-01215-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41416-020-01215-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,14]],"date-time":"2021-12-14T01:03:35Z","timestamp":1639443815000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41416-020-01215-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,12,14]]},"references-count":11,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2021,3,16]]}},"alternative-id":["1215"],"URL":"https:\/\/doi.org\/10.1038\/s41416-020-01215-7","relation":{},"ISSN":["0007-0920","1532-1827"],"issn-type":[{"value":"0007-0920","type":"print"},{"value":"1532-1827","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,12,14]]},"assertion":[{"value":"12 November 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 November 2020","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 November 2020","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 December 2020","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All informed consents were obtained. This report does not contain any individual person\u2019s information.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to publish"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Data availability"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"M.G.W. is supported through the National Institute of Health Kirschtein National Research Service (T32) Award.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding information"}}]}}